A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress


Creative Commons License

Kato K., Shah M., Enzinger P., Bennouna J., Shen L., Adenis A., ...Daha Fazla

Annals of Oncology, cilt.29, 2018 (SCI-Expanded, Scopus)